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Abstract 
Photodynamic therapy (PDT) is a promising treatment that has continued to improve over the 
past thirty years when the first commercially approved photosensitizer (PS) was introduced.  
Although PDT has many successful applications, the terrifying number of new cancer cases 
reported each year makes scientists focus their efforts towards the development of new efficient 
PS for PDT.  The biggest obstacle that prohibits PDT from becoming a more widely used 
therapy is the ineffective photosensitizers (PS) that are available on the market today.  The 
purpose of this study was to evaluate the synthesized metal-porphyrin complex as a possible 
candidate as a PS. The metalloporphyrin was synthesized from the combination of 
protoporphyrin and europium.  The experiments performed in this research to evaluate the new 
drug were spectroscopic measurements, DNA photocleavage studies, phototoxic tests, and 
DNA binding.  The results obtained provide this new drug, which is in its initial developing 
stages, with great future potential in the PDT field.  
 
 
 
 
 
 
 
 
 
I. Introduction 
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According to the National Cancer Institute, there was about 1.5 million new cancer cases in the 
United States in 2009 [6].  The most frequent procedures to treat cancer are chemotherapy, 
radiation therapy or surgery.  Although these treatments have been proven effective they came 
attached with a high health risk due to their harmful side effects.  The scientists has been 
looking for more noble therapies that do not involve the life threatening side effects that 
chemotherapy, radiation therapy, or surgery have.  Among the new treatments available, 
Photodynamic therapy (PDT) has gained much attention in the past 30 years with the 
introduction of the first commercially available drug Photofrin® (Porfimer Sodium) and the 
publications of the successful treatment of lesions using PDT by Dougherty et al [3].   Since then, 
PDT has shown great potential for diverse types of cancer with only mild side effects.  For 
example, PDT using the drug Porfimer Sodium (Photofrin®) was approved for the treatment of 
oseophageal cancer in the United States, for the treatment of early and late stage lung cancer in 
the Netherlands, bladder and oesophageal cancer in Canada, and lastly, for early stage lung 
cancer, oseophageal cancer, gastric cancer, and cervical cancer in Japan [1].  
One of the most appealing aspects of PDT is that it is a minimal invasive treatment and it has 
low side effects [8]. PDT uses a photosensitizing drug, also called photosensitizer (PS), to 
transfer energy from a specific source of light to cellular oxygen to create reactive oxygen 
species and induce cell death [7]. Since the drugs available on the market today for PDT use are 
not very effective, a high concentration of the drug is needed to produce an acceptable 
phototherapeutic response.  Although photosensitizers (PSs) are more selective towards tumors 
than healthy tissue [7], the drug normally ends up accumulating in cutaneous tissue leaving 
patients with skin photosensitivity [5] [14].  Consequently, patients in PDT treatment have to avoid 
the exposure to direct sunlight for several days (normally at least 2 to 3 weeks [1] [4]) in order to 
prevent sunburn [2].  Scientists have seen that one of the major barriers that PDT has is the poor 
effective drugs and therefore, there is much effort today in the PDT investigational field to 
produce second and third generation drugs that are more effective and selective than the first 
generation PSs [4]. 
The purpose of this study was to develop and evaluate a porphyrin derivative complex as a 
possible photosensitizer for PDT.  The PS was synthesized in-house using protoporphyrin as a 
ligand and inserting the lanthanide europium to the center of the tetrapyrrole macrocycle.  The 
porphyrins that are in the market such us Photofrin and other like sensitizers have weak 
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absorbances in the optimal phototherapeutic region with the absorbing band at around 630nm 
[12]
.   It is known that metal ions that are attached to porphyrins change the photophysical 
properties of the macrocycle providing the new molecule with innovative characteristics [11].  The 
insertion of the Europium in the center of the macrocycle was used to enhance the absorption 
properties of the new synthesized metal complex.  In order to evaluate the porphyrin-lanthanide 
complex effectiveness as a PS, absorbance and fluorescence spectroscopy studies, DNA 
Biding studies, DNA photo cleavage studies, and median lethal dose (LC50) cell studies were 
performed.   Even though it was understood that the new complex is in the first stages of 
development the studies performed in this research provided with the basic necessary 
information needed to understand the possible efficiency of the synthesized compound as a 
photosensitizer. 
The characteristics desired in a PS to be consider effective are to be selective towards the 
target tumor, low side effects, chemically pure, low dark toxicity and high toxicity when 
activated, absorption wavelength in the red visible region from 600nm to 800nm for deep tissue 
penetration of the incident light, easily available, and low cost [9][12].  Generally, PSs come from 
three main families, porphyrins, chlorophyll derivatives, and dye substances [9].  The mechanism 
of energy transfer employed by the PS can be followed by the Jablonski diagram in figure 1.  
First, the PS is excited by a specific source of light from its ground state (S0) to a short live 
singlet state (S1).  Then, from the S1 it can return to the S0 by radiative and non radiative decay. 
During non radiative decay the PS undergoes intersystem crossing (ISC) producing a longer 
lifetime triple state (T1).  From T1 the PS goes back to S0 as phosphorescence where it can also 
transfer energy to other molecules present in the environment by a type I or type II reaction.  In 
a type I reaction, electron transfer from the PS produces free radicals which they react with 
cellular oxygen producing superoxide and peroxide oxygen anions.  In a type II reaction, the PS 
directly transfers energy to molecular oxygen from the excited T1 to triplet ground state oxygen 
producing reactive oxygen species.
 
The type I or type II reaction triggers oxidative stress on the 
cell producing cellular death
 
[8] [1]
. 
The synthesized metalloporphyrins showed some of the desirable characteristics in good PS.  
However, the main purpose of this study was to provide with the basic studies to support the 
synthesized marocyclic molecule in it initial stage of drug development.  There are many futures 
that can be later added to the molecule to improve its selectivity toward cancerous tissue, its 
intermolecular localization, and its effective delivery to targeted tissue.  
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S.K. Pushpan, et al., Curr. Med. Chem. – Anti-Cancer Agents 2 (2002), 187-207. 
 
Figure 1.  Pictoral representation of the Jablonski diagram to represent the mechanism of energy 
transfer employed by photosensitizers. 
II. Materials and methods 
II.I. Synthesis and purification of the Metalloporphyrin 
The synthesis was carried according to literature. The Protoporphyrin 95% was purchased from 
Sigma Aldrich with a lot P8293-G.  Shortly, Europium oxide was combined with protoporphyrin 
and deionized (DI) water in a round flask. Reflux was conducted for 72 hours under 90°C to 
100°C.  The product was washed with DI Water, filtered, and dried. The compound was purified 
by column chromatography using the size exclusion bed Sephadex G-15. 
II.II. Spectroscopic Studies 
To obtain the absorbance spectrum of the metalloporphyrins and the protoporphyrin, both 
compounds were dissolved in dimethyl sulfoxide (DMSO) to a concentration of 200µM. The 
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ultraviolet and visible (UV-VIS) spectrum of the compounds was measured using an Ocean 
Optics USB4000 spectrometer, refer to Figure 4.  The fluorescence spectrum of the metal-
porphyrin complex and the ligand was measured using an Ocean Optics USB2000+ 
spectrometer (spectrums can be observed in figure 4). Both compounds were diluted to a 
concentration of 100µM.  The infrared (IR) spectrum for the metalloporphyrins and the 
protoporphyrin was acquired using a Thermo Fisher equipped with an attenuated total 
reflectance (ATR) accessory (refer to figure 3). Both compounds were dissolved in DMSO to a 
total concentration of 200µM. 
II.III.  DNA binding studies 
For this study a titration assay method was employed to calculate the DNA binding constant.  
Briefly, the metalloporphyrins was dissolved in DMSO to a total concentration of 100µM. The 
absorbance of the solution was measured at intervals of 5 minutes with the addition of 10µL of 
CT-DNA using an Ocean Optics USB4000 spectrometer. The following equation was used: 
ε
a
-εf / εb-εf = 1/Kb [DNA] +1 
To Produce the Stern-Volmer plot and calculate the Stern-Volmer constant the same titration 
method was used as described above for the DNA binding constant but instead of the 
absorbance the fluorescence of the solution was measured using an Ocean Optics USB2000+ 
spectrometer. The following equation was used to calculate the Stern-Volmer constant: 
Fo/F=1+Ksv[Q] 
II.III.  DNA Photocleavage Studies 
 The agarose gel was prepared in house with a concentration of 1.4%. 10µL of plasmid DNA 
and 10µL of the metal-porphyrin complex were one hour and then photo-irradiated for one hour. 
The dye was added to the mixture and then the mixture was loaded into the agarose gels wells. 
Electrophoresis was performed for 80 minutes at 70v. 
II.IV.  LD50 Studies 
The cells were growth with an enrichment media. The media was washed off with PBS and the 
Drug was added. The cells were incubated for a few hours and then the cells were reacted in a 
dark and lighted environment. The drug was washed away and enrichment media was added to 
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the cell cultures. The plates were incubated until the control group reached an 80% 
concentration.  The media was washed off and the cells were burst with a detergent solution. At 
this point the albumin standard solution was added and incubated for few hours. A plate counter 
was used to quantify the cells. 
 
III. Results and Discussion 
III.I. Synthesis 
The synthesis proceeded as the literature indicated and the molecular structure of the 
synthesized metalloporphyrins can be viewed in figure 2.  The results gained during the 
spectroscopy studies confirmed the successful insertion of the metal in the tetrapyrrolic 
macrocycle. The IR spectrums form the ligand and the metal-porphyrin complex showed a 
hypsochromic  shift for the band at around 1000 cm-1, which can be observed in figure 3. The IR 
spectrum of the metalloporphyrin had a band at 1018.2cm-1 while the ligand exhibits the 
corresponding band at 1019.7cm-1 in its IR spectrum.  The same structural confirmation was 
observed with a red shift produced in the metalloporphyrins for three of the visible absorbance 
bands.  The lambda maximum (λ max) obtained for those three bands are 505.5nm, 539.8nm, 
and 575.1nm.  The equivalent λ max for the ligand were obtained at 503.5nm, 539.6nm, and 
573.4nm; which can be seen in figure 4. 
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Figure 2. Pictorial representation of the synthesis process for the metalloporphyrin. 
  
Figure 3.  The IR spectrum to the left belongs to the metalloporphyrins. The IR spectrum to the 
right corresponds to the protoporphyrin.  
III.II. Spectroscopic studies 
The UV-VIS spectrum obtained for the metal-porphyrin complex shows four distinct bands with λ 
max at 505.5nm, 539.8nm, 575.1nm, and 629nm; they can be seen in figure 4. The molar 
absorptivity (ε) calculated for these four λ max are 3670.0 M-1 cm-1, 2905.7 M-1 cm-1, 1916.0 M-1 
cm-1, and 1345.8 M-1 cm-1 respectively.  The UV-VIS spectrum for protoporphyrin provided with 
four bands with a λ max at 503.5nm, 539.6nm, 573.4nm, and 629nm.  According to the literature 
the commercial PS Photofrin has a ε of 1170 M-1 cm-1 [12]. The insertion of the metal in the 
tetrapyrrolic macrocycle enhanced the absorption of the ligand providing the metalloporphyrin 
with a stronger ε than a commercially available drug.   This absorption improvement is also 
reflected in the fluorescence spectroscopic studies. 
The Fluorescence spectrum gather for the protoporphyrin exhibited two bands with a 
fluorescence maximum at 631nm and 678nm (figure 4) and an intensity of 1895.6 counts and 
3162.8 counts respectively.  The fluorescence spectrum collected for the metalloporphyrins 
provided with two districts fluorescence maximum at 631nm and 678 nm, refer to figure 4.  The 
fluorescence intensity for those two bands is 20273.76 counts and 5911.5 counts respectively.  
The enhance fluorescence by the metal insertion into the core of the ligand macrocycle 
coincides with the data obtained by the absorption spectroscopy studies.  This can indicate a 
great potential for this new metal-porphyrin complex since it already shows some Photophysical 
properties better than the available drugs in the market. 
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Figure 4. The UV-VIS spectrum on the left corresponds to the metalloporphyrin in DMSO. The 
UV-VIS spectrum to the right belongs to the protoporphyrin in DMSO. 
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Figure 5. The fluorescence spectrum to the left belongs to metalloporphyrins. The fluorescence 
spectrum to the right corresponds to the protoporphyrin.  
 
III.III. DNA binding studies 
One resourceful ways to induce cell death is to cleave DNA.  Therefore, binding DNA properties 
of the PS are a good source to measure the photosensitizer’s potential efficacy in PDT.  The 
binding constant (Kb) was obtained from figure 6 at 1.76X103 M-1. The low Kb calculated is 
thought to be due to the possible fact that the metalloporphyrin does not bind directly to the 
DNA.  However, it binds indirectly with a distance enough to allow energy transfer.  This energy 
transfer is supported by the Stern-Volmer plot generated using the DNA titration method. 
 
Figure 6. DNA binding constant graph, data obtained from the DNA titration assay.  
The Stern Volmer plot is a good indicator for the intermolecular deactivation capabilities of 
molecules.  In this case it was used to measure the quenching ability of the DNA to the excited 
metalloporphyrins. The data obtained for this study was plotted in a graph and the results can 
be observed in figure 7. The Stern-Volmer constant (Kq) acquired from the slope of the graph is 
1.29X104 M-1, which shows the good quenching capacity that the DNA towards the synthesized 
metal-porphyrin complex.  
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Figure 7. Sterm-Volmer plot for the DNA binding assay. 
III.IV. DNA photocleavage 
The effectiveness of the synthesized molecule to cleave DNA can be seen in the results 
obtained for the DNA Photocleavage assay.  From left to right wells number 1, 2, 3, 5, and 7 
were loaded with DNA only and wells number 4, 6, and 8 were loaded with DNA; both gels were 
prepared the same way. The appearance of two bands on wells 4, 6 and 8 in both gels indicates 
that protoporphyrin can cleave DNA with or without the presence of a Europium in its molecular 
structure.   Nevertheless, the wells 4, 6, and 8 in the protoporphyrin gel are stronger in 
appearance than in the metalloporphyrins gel.  This indicates that Europium can aid in 
decreasing the toxicity of protoporphyrin.  
Page 12 of 16 
 
 
Figure 8. The agarose gel to the left belongs to the metalloporphyrins and the agarose gel to the 
right belongs to the protoporphyrin. 
III.V. LD50 studies 
The dark and light toxicity of the synthesized metalloporphyrins was evaluated with the 
LD50 study. The data obtained was plotted in a graph, which can be seen in figure 9. The 
calculated LC50 from the graph is 500µM, which indicates that the metalloporphyrins has good 
toxicity when activated by light and low toxicity when is not activated in the dark. This is an 
important feature to PSs need to have in order to be voluble for PDT [12]. 
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Figure 9. LC50 graph showing the light and dark toxicity of the metal-porphyrin complx. 
IV. Conclusion 
A nonexistent efficient photosensitizer in the market for PDT creates a big urge in the scientific 
field for the search of the ideal PS. This was the purpose of this study and the results obtained 
provided useful and promising insight on the europium-porphyrin complex synthesized. The fact 
that the ε obtained from the spectroscopy studies is greater than the Photofrin ε, which is a 
widely use PS in the PDT field, gives the metalloporphyrin already a good starting point.  
An impressive point of this new synthesized molecule is its good phototoxicity and low dark 
toxicity showed in this investigation as well as its ability to effectively bind and cleave DNA.  
Although the synthesized drug is still in its first baby steps of development, there is a lot work 
done by other scientists with second and third generation PS that can enrich the future of this 
noble drug. 
For example, second generation PS are characterized by the addition of chromophoric 
structures to existing drugs to improve their absorption to the far red visible region (650nm to 
800nm)[5].  This can allow the PS to be used in PDT and improve its ability to work in deep 
tissue areas.  On the other hand, Third generation PS are known for their ability to be more 
selective towards cancerous tissue.  Some scientists reported enhanced selectivity of the PS by 
the addition of tumor specific monoclonal antibodies [13]. Lastly, the delivery of the PS to its final 
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destination cannot be ignored since it is an area highly studied by the nanotechnology field.  
Scientists are producing nonocrriers that boost the therapeutic response by efficiently delivering 
the PS its final destination [1]. 
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